Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Surzebiclimab (BGB-A425), a humanized variant IgG1 monoclonal antibody, targets and binds with high affinity (K D = 0.36 nM) and specificity to the extracellular domain of T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). This compound is utilized in cancer research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Surzebiclimab (BGB-A425), a humanized variant IgG1 monoclonal antibody, targets and binds with high affinity (K D = 0.36 nM) and specificity to the extracellular domain of T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). This compound is utilized in cancer research [1]. |
In vitro | Surzebiclimab (BGB-A425; 0.1-100 μg/mL) effectively inhibits the interaction between Tim-3 and PtdSer. This compound enhances IFN-γ production in primary T cells and natural killer (NK) cell mediated cytotoxicity against tumor cells [1]. When used alone or in combination with the anti-PD-1 antibody BGB-A317, Surzebiclimab augments T cell responses to allogeneic antigens. Additionally, it induces the internalization of the Tim-3 receptor on the cell surface [1]. |
In vivo | Surzebiclimb (BGB-A425) in combination with BGB-A317 inhibits tumor growth in a murine xenograft tumor model [1]. |
Synonyms | BGB-A425 |
Molecular Weight | N/A |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Surzebiclimab BGB-A 425 BGB-A425 BGB-A-425 inhibitor inhibit